MD Anderson Cancer Center and Rigel Pharmaceuticals Collaborate to Advance Evaluation of Olutasidenib in Hematologic Cancers
Shots:
- The collaboration between MD Anderson and Rigel Pharmaceuticals is focused on assessing olutasidenib's potential for treating newly diagnosed & r/r patients with AML, higher-risk MDS, and MPN.
- Under the collaboration Rigel will contribute $15M in milestone payments & study materials throughout the five-year collaboration, with the company maintaining exclusive rights to its programs within the partnership
- Rigel and MD Anderson will jointly lead clinical development efforts through a joint steering committee. Olutasidenib is already been approved by the US FDA for the treatment of adult patients with R/R AML with a susceptible IDH1 mutation
Ref: MD Anderson Cancer Center | Image: Rigel Pharmaceuticals
Related News:- Rigel Entered into an Exclusive WW License Agreement with Forma to Develop and Commercialize Olutasidenib for Acute Myeloid Leukemia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
